Interim Management Statement
Introduction
I am pleased to present the Company's interim management statement for the
period from 1 April 2010 to 26 July 2010 as required by the UK Listing
Authority's Disclosure and Transparency Rule 4.3.
Performance and dividends
The Company's unaudited net asset value (NAV) as at 30 June 2010 was £26.3
million (31 March 2010: £26.8 million) or 86.8 pence per share (31 March
2010: 88.3 pence per share). The net asset value for 30 June 2010 is after
accounting for the first dividend for the year to 31 March 2011 of 1.5 pence per
share (total cost: £454,000), to be paid 6 August 2010 to shareholders on the
register as at 9 July 2010.
The net asset value remains broadly the same as the net asset value at 31 March
2010. Encouragingly, revenue return has increased due to the increased rate of
investment.
The Board is not aware of any significant events or transactions between 30 June
2010 and the date of this interim management statement which would have a
material impact on the net asset value of the Company.
Share buybacks
During the period from 1 April 2010 to 26 July 2010, the Company purchased
22,544 shares at an average price of 75 pence per share, to be held in treasury.
The current share price is 75 pence.
Portfolio
Further investments have been made during the period from 1 April 2010 to 26
July 2010:
+-----------------------------------+------+-----------------------------------+
|Name |£000's|  |
+-----------------------------------+------+-----------------------------------+
|Masters Pharmaceuticals Limited |980 |International specialist |
| | |distribution of pharmaceuticals |
+-----------------------------------+------+-----------------------------------+
|BBVA Senior Finance floating rate |3,000 |Floating rate note |
|note: maturity date 8 November 2011| | |
+-----------------------------------+------+-----------------------------------+
Disposals
There were no disposals during the period from 1 April 2010 to 26 July 2010.
Top ten holdings (as at 26 July 2010)
+---------------------------------------------------------------------+------+
|Investment |Value |
| |£000's|
+---------------------------------------------------------------------+------+
|BBVA Senior Finance floating rate note: maturity date 8 November 2011|3,000 |
+---------------------------------------------------------------------+------+
|UBS floating rate note: maturity date 20 May 2011 |2,525 |
+---------------------------------------------------------------------+------+
|Geronimo Inns I VCT Limited |1,589 |
+---------------------------------------------------------------------+------+
|Geronimo Inns II VCT Limited |1,589 |
+---------------------------------------------------------------------+------+
|Bravo Inns II Limited |1,393 |
+---------------------------------------------------------------------+------+
|Taunton Nursing Home Limited |1,014 |
+---------------------------------------------------------------------+------+
|Prime Care Holdings Limited |991 |
+---------------------------------------------------------------------+------+
|Masters Pharmaceuticals Limited |985 |
+---------------------------------------------------------------------+------+
|Forth Photonics Limited |925 |
+---------------------------------------------------------------------+------+
|Mi-Pay Limited |808 |
+---------------------------------------------------------------------+------+
Further information regarding historic and current financial performance and
other useful shareholder information can be found on the Fund's website
underwww.albion-ventures.co.uk/Our Funds/Albion Enterprise VCT PLC.
Maxwell Packe, Chairman
26 July 2010
For further information please contact:
Patrick Reeve, Albion Ventures LLP - tel: 020 7601 1850
[HUG#1434010]
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Albion Enterprise VCT PLC via Thomson Reuters ONE
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.